You are here

Sarel Fleishman


A new algorithm may greatly speed up the process of engineering therapeutic antibodies

An illustration showing four modular enzyme fragments (highlighted) that Weizmann Institute’s CADENZ method can combine to generate active enzymes at a hitherto unseen rate

In a major step toward greener industry, Weizmann Institute scientists create a computational method for generating enzymes with unprecedented...

Dr. Shiran Barber-Zucker and Prof. Sarel Fleishman. Protein Goldmine

Forget crystals. AI gives Weizmann’s algorithms the means to design biomolecules with a huge range of valuable functions

Evolved to Stop Bacteria, Designed for Stability

New proteins, created through long-distance collaboration, might lead to the reversal of antibiotic resistance in certain bacteria 

Prof. Sarel Fleishman. His research has already led to the design of a potential malaria vaccine, and he is now concentrating his efforts on the coronavirus

Weizmann Institute scientists have developed a research platform for designing tiny antibodies that can halt the virus infection process

p loops

Proto-enzymes designed in the lab bound strongly to RNA and DNA, suggesting a surprising origin for these proteins

Medicinal Chemistry

The Institute will fund innovative research on compounds that hold promise for becoming therapies for a range of human diseases and...

Fleishman and group

A computational method for designing dramatically more efficient versions of enzymes may lead to new avenues of drug design and new treatments...

Dr. Sarel Fleishman

Dr. Sarel Fleishman is the recipient of a Morris L. Levinson Prize in Biology awarded by the Scientific Council

Designed and experimental antibody

Including “non-ideal” components in the designs may be key to functional artificial proteins